{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:15:16Z","timestamp":1760908516498,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.biopha.2009.04.035","type":"journal-article","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T04:12:36Z","timestamp":1257480756000},"page":"107-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab"],"prefix":"10.1016","volume":"64","author":[{"given":"Akihiko","family":"Ban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Furumitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yukioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2009.04.035_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/ard.61.9.818","article-title":"Living with rheumatoid arthritis: expenditures, health status and social impact on patients","volume":"61","author":"Lapsley","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.biopha.2009.04.035_bib2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/art.1780240315","article-title":"The impact of chronic disease: a sociomedical profile of rheumatoid arthritis","volume":"24","author":"Meenan","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.biopha.2009.04.035_bib3","first-page":"722","article-title":"Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics","volume":"52","author":"Feldmann","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.biopha.2009.04.035_bib4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ncprheum0797","article-title":"Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis","volume":"4","author":"Moss","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.biopha.2009.04.035_bib5","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.04.035_bib6","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.biopha.2009.04.035_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10067-008-0850-z","article-title":"Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis","volume":"27","author":"Kanbe","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.biopha.2009.04.035_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/ard.2003.017160","article-title":"Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis","volume":"64","author":"Breedveld","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.biopha.2009.04.035_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/ar144","article-title":"The stressed synovium","volume":"3","author":"Schett","year":"2001","journal-title":"Arthritis Res"},{"key":"10.1016\/j.biopha.2009.04.035_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0034-5687(99)00092-4","article-title":"The effects of mechanical forces on lung functions","volume":"119","author":"Wirtz","year":"2000","journal-title":"Respir Physiol"},{"key":"10.1016\/j.biopha.2009.04.035_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.biopha.2009.04.035_bib12","first-page":"1352","article-title":"Interleukin-1beta induces elevation of spermidine\/spermine N1-acetyltransferase activity and an increase in the amount of putrescine in synovial adherent cells from patients with rheumatoid arthritis","volume":"27","author":"Furumitsu","year":"2000","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.biopha.2009.04.035_bib13","first-page":"64","article-title":"Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis","volume":"27","author":"Furumitsu","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.biopha.2009.04.035_bib14","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/art.11327","article-title":"Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis","volume":"48","author":"Nagata-Sakurai","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.biopha.2009.04.035_bib15","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.cardfail.2007.06.730","article-title":"Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy","volume":"13","author":"Ohtsuka","year":"2007","journal-title":"J Card Fail."},{"key":"10.1016\/j.biopha.2009.04.035_bib16","unstructured":"Wells GA, Becker JC, Teng J, Dougados M, Schiff MH, Smolen JS, Aletaha D, van Riel PL. Validation of the Disease Activity Score 28 (DAS28) and EULAR response criteria based on CRP against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on ESR. Ann Rheum Dis. in press."},{"issue":"1","key":"10.1016\/j.biopha.2009.04.035_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.1780350102","article-title":"AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire","volume":"35","author":"Meenan","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.biopha.2009.04.035_bib18","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/ard.2007.069765","article-title":"Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment","volume":"66","author":"ten Klooster","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.biopha.2009.04.035_bib19","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0026-0495(99)90227-5","article-title":"Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism","volume":"48","author":"Inaba","year":"1999","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.biopha.2009.04.035_bib20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.2006.054205","article-title":"Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values","volume":"66","author":"Inoue","year":"2007","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"10.1016\/j.biopha.2009.04.035_bib21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-3083.2006.01840.x","article-title":"Anti-TNF effects on destructive fibroblasts depend on mechanical stress","volume":"64","author":"Lange","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.biopha.2009.04.035_bib22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1055\/s-2008-1070771","article-title":"Structural basis and pathomechanisms of arthritis and arthrosis","volume":"105","author":"Fassbender","year":"1980","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.biopha.2009.04.035_bib23","first-page":"568","article-title":"The validity of pooled outcome measures (indices) in rheumatoid arthritis clinical trials","volume":"20","author":"Boers","year":"1993","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.biopha.2009.04.035_bib24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2007.081984","article-title":"Psychometric properties of the Rheumatoid Arthritis Disease Activity Index (RADAI) in a cohort of consecutive Dutch patients with RA starting anti-tumour necrosis factor treatment","volume":"67","author":"Veehof","year":"2008","journal-title":"Ann Rheum Dis"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209001000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209001000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:44:35Z","timestamp":1760093075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332209001000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0753332209001000"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2009.04.035","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2009.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}